Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient.
A highly human leukocyte antigen-sensitized heart transplant candidate underwent immunomodulation with intravenous gamma globulin and cyclophosphamide. His panel reactive antibody screen fell from 64% to 14%. He underwent successful orthotopic heart transplantation with a histoincompatible, T-cell cross-match-negative heart without the development of hyperacute rejection. The combination of intravenous gamma globulin and cyclophosphamide may be a simple and effective means to overcome the human leukocyte antigen-barrier in sensitized heart transplant candidates.
De Marco
T
T
Division of Cardiology, University of California, San Francisco 94143-0124, USA.
Damon
L E
LE
Colombe
B
B
Keith
F
F
Chatterjee
K
K
Garovoy
M R
MR
D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006333:Heart Failure / Q000276:immunology / Q000628:therapy*; D016027:Heart Transplantation / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007519:Isoantigens / Q000097:blood*; D008297:Male; D008875:Middle Aged
D007166:Immunosuppressive Agents; D007519:Isoantigens; D003520:Cyclophosphamide